Fishman Jay A Ltd. MI Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Fishman Jay A Ltd. MI trimmed its position in Pfizer Inc. (NYSE:PFE) by 3.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 709,510 shares of the biopharmaceutical company’s stock after selling 24,883 shares during the period. Pfizer comprises 5.2% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 6th biggest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $25,330,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer in the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer in the 2nd quarter worth $103,000. D. Scott Neal Inc. increased its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new position in shares of Pfizer in the 2nd quarter worth $120,000. Finally, Private Vista LLC increased its holdings in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the last quarter. 69.87% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. UBS Group set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $39.25.

Shares of Pfizer Inc. (NYSE PFE) traded down $0.22 during trading on Friday, reaching $36.61. 24,115,126 shares of the company’s stock traded hands, compared to its average volume of 20,260,000. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $218,220.00, a PE ratio of 10.40, a PEG ratio of 2.20 and a beta of 0.94. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the business posted $0.47 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.71%. Pfizer’s payout ratio is currently 38.64%.

Pfizer announced that its board has initiated a share buyback plan on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Fishman Jay A Ltd. MI Reduces Holdings in Pfizer Inc. (NYSE:PFE)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/04/pfizer-inc-pfe-shares-sold-by-fishman-jay-a-ltd-mi.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply